Sells portable fingerprint-sweat drug screening systems, including single-use cartridges and handheld readers, to safety-critical businesses, drug treatment organizations, and judicial organizations.
10-K for FY2026, filed Aug 19, 2026
Customers buy cartridges, readers and accessories as goods; sales are counted when shipped or received, depending on the sale terms, and some customers pay before delivery.
10-K for FY2026, filed Aug 19, 2026In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue at a point in time when it satisfies its…View ↗
10-K for FY2026, filed Aug 19, 2026
FY2026 revenue by product or service ↗$4.2M
10-K for FY2026, filed Aug 19, 2026
$4.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Sales of Goods - Cartidges
Sold outright
10-K for FY2026, filed Aug 19, 2026 |
59%
FY2023: 58%
|
Sales of Goods - Cartidges, FY2026
$2.5M Sources
|
Sold outright |
|
Sales of Goods - Readers
Sold outright
10-K for FY2026, filed Aug 19, 2026 |
21%
FY2023: 27%
|
Sales of Goods - Readers, FY2026
$902.3K Sources
|
Sold outright |
|
Other sales - accessories
Sold outright
10-K for FY2026, filed Aug 19, 2026 |
20% |
Other sales - accessories, FY2026
$827.3K Sources
|
Sold outright |
Small and medium-sized businesses, including employers in safety-critical industries, buy through the UK direct-sales team, an Australian sales agency, and distributors that resell products; drug-treatment and judicial organizations are also customers.
10-K for FY2026, filed Aug 19, 2026We currently serve over 502 small to medium-sized businesses, primarily located in the United Kingdom, with additional customers across…View ↗
Distributors: Through buy-sell agreements, distributors will purchase the IFP Products and resell them to customers. These distributors can…View ↗
United Kingdom: Our direct sales team consists of five sales representatives and a National Sales Manager under the direction of the Vice…View ↗
Australia: We utilize a third-party sales agency under the direction of the Vice President of Global Sales. The agency’s primary area of…View ↗
Intelligent Fingerprinting Platform: The Company’s current active product is the Intelligent Fingerprinting Platform, a proprietary…View ↗
10-K for FY2026, filed Aug 19, 2026
Major Customer - One customer accounted for 4.9% and 8.9% of revenues for the years ended June 30, 2026 and 2025, respectively.View ↗
No. It lost $12.4M in FY2026.
10-K for FY2026, filed Aug 19, 2026
−$12.6MView ↗
10-K for FY2026, filed Aug 19, 2026
−$12.4MView ↗
10-K for FY2026, filed Aug 19, 2026
−$12.1MView ↗
Growing. Revenue grew 3.4x in 3 years, from $1.3M in FY2023 to $4.2M in FY2026, about 50% a year.
Biosensor development paused
The earlier report described a saliva-glucose test candidate on a licensed biosensor platform; the latest says further development is postponed until licensing arrangements can be finalized, while identifying fingerprint testing as the active product.
10-K for FY2023, filed Aug 23, 2023 10-K for FY2026, filed Aug 19, 2026The Biosensor Platform – Our “Biosensor Platform” consists of a small, printable modified organic thin-film transistor strip that we…View ↗
Adds wearable drug testing
The older report centered on fingerprint drug testing and a saliva-glucose biosensor candidate; the latest report adds SMARTOX's SmarTest Patch, a wearable for continuous drug detection through sweat.
10-K for FY2023, filed Aug 23, 2023 10-K for FY2026, filed Aug 19, 2026On July 15, 2025, the Company announced the addition of the SmarTest® Patch to its portfolio of non-invasive drug testing solutions. The…View ↗
Loading...